Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.

@article{Yang2013PromisingBF,
  title={Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.},
  author={Zuyao Yang and Xin Yin Wu and Ya-fang Huang and Meng-Yang Di and Da-yong Zheng and Jin-zhang Chen and Hong Ding and Chen Mao and Jin-Ling Tang},
  journal={International journal of cancer},
  year={2013},
  volume={133 8},
  pages={1914-25}
}
KRAS mutations have been established as a major predictive biomarker for resistance to the treatment of metastatic colorectal cancer (mCRC) with anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR MoAbs). However, many patients with KRAS wild-type tumors still do not respond to the treatment. We conducted a systematic review with meta… CONTINUE READING